Diagnosis and management of testosterone deficiency

Asian Journal of Andrology

Volumn 17, Issue 2, 2015, Pages 177-186

  McBride, James A ^a   Carson, Culley C ^a   Coward, Robert M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

androgens; erectile dysfunction; hormones; hypogonadism; testosterone

Indexed keywords

GLUCOCORTICOID; OPIATE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BONE DENSITY; HUMAN; LABORATORY DIAGNOSIS; PHYSIOLOGY; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SUPPLEMENTATION THERAPY; ADVERSE EFFECTS; AGED; AGING; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPLICATION; DEFICIENCY; DIAGNOSTIC TEST; DISEASE MANAGEMENT; ERECTILE DYSFUNCTION; EUNUCHISM; HORMONE SUBSTITUTION; MALE; METABOLISM; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; COMORBIDITY; DIAGNOSTIC TESTS, ROUTINE; DISEASE MANAGEMENT; ERECTILE DYSFUNCTION; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 84924649961     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.143317     Document Type: Review

References (150)

1. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-94.
2. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23-32.
3. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab 2008; 93: 2737-45.
4. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.
5. Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab 2008; 93: 3870-7.
6. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-7.
7. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-6.
8. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res 1995; 43: 25-8.
9. McGill JJ, Shoskes DA, Sabanegh ES. Androgen deficiency in older men: indications, advantages, and pitfalls of testosterone replacement therapy. Cleve Clin J Med 2012; 79: 797-806.
10. Hall SA, Araujo AB, Esche GR, Williams RE, Clark RV, et al. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med 2008; 168: 1070-6.
11. Turek PJ. Male reproductive physiology. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters AP, editors. Campbell-Walsh Urology. 10 th ed. Philadelphia: Elsevier-Saunders; 2012. p. 591-615.
12. Bhasin S, Zhang A, Coviello A, Jasuja R, Ulloor J, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008; 73: 1311-7.
13. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-13.
14. th ed. Stamford Connecticut: Appleton and Lange; 1997. p. 422-52.
15. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau JL, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002; 8: 440-56.
16. Jarow JP, Chen H, Rosner TW, Trentacoste S, Zirkin BR. Assessment of the androgen environment within the human testis: minimally invasive method to obtain intratesticular fluid. J Androl 2001; 22: 640-5.
17. Pantalone KM, Faiman C. Male hypogonadism: more than just a low testosterone. Cleve Clin J Med 2012; 79: 717-25.
18. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278-81.
19. Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007; 67: 853-62.
20. Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007; 100: 509-13.
21. Smith RP, Coward RM, Kovac JR, Lipshultz LI. The evidence for seasonal variations of testosterone in men. Maturitas 2013; 74: 208-12.
22. Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, et al. The laboratory diagnosis of testosterone deficiency. Urology 2014; 83: 980-8.
23. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
24. Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, et al. Guidelines on male hypogonadism. Arnhem: European Association of Urology; 2012. p. 2-28.
25. rd ed. Berlin: Springer; 2010. p. 169-92.
26. Guay A, Seftel AD, Traish A. Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses. Int J Impot Res 2010; 22: 9-19.
27. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003; 88: 622-6.
28. Tanrikut C, Goldstein M, Rosoff JS, Lee RK, Nelson CJ, et al. Varicocele as a risk factor for androgen deficiency and effect of repair. BJU Int 2011; 108: 1480-4.
29. rd ed. Berlin: Springer; 2010. p. 193-238.
30. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009; 55: 121-30.
31. Morales A, Lunenfeld B, International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002; 5: 74-86.
32. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810-8.
33. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-64.
34. Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 2009; 117: 38-43.
35. Morrison D, Capewell S, Reynolds SP, Thomas J, Ali NJ, et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med 1994; 88: 659-63.
36. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55: 39-65.
37. Holma PK. Effects of an anabolic steroid (metandienone) on spermatogenesis. Contraception 1977; 15: 151-62.
38. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367: 1412-20.
39. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med 1990; 18: 429-31.
40. Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, et al. Anabolic steroid induced hypogonadism in young men. J Urol 2013; 190: 2200-5.
41. Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 2012; 15: 296-302.
42. Dev R, Del Fabbro E, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007; 110: 1173-7.
43. Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain 2006; 7: 200-10.
44. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 2007; 36: 333-48.
45. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009; 25: 170-5.
46. Mendelson JH, Inturrisi CE, Renault P, Senay EC. Effects of acetylmethadol on plasma testosterone. Clin Pharmacol Ther 1976; 19: 371-4.
47. Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 2002; 18: 144-8.
48. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3: 377-84.
49. Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril 2010; 94: 1021-6.
50. Bell S, Shipman M, Bystritsky A, Haifley T. Fluoxetine treatment and testosterone levels. Ann Clin Psychiatry 2006; 18: 19-22.
51. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013; 11: 57.
52. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-9.
53. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76: 1140-6.
54. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673-80.
55. Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008; 4: 415-9.
56. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-6.
57. Meston N, Davies RJ, Mullins R, Jenkinson C, Wass JA, et al. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med 2003; 254: 447-54.
58. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-92.
59. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-50.
60. Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. testicular function. Gynecol Endocrinol 2008; 24: 33-9.
61. Guay AT, Traish A. Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am 2011; 38: 175-83.
62. Emanuele MA, Emanuele NV. Alcohol's effects on male reproduction. Alcohol Health Res World 1998; 22: 195-201.
63. Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444-50.
64. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS 2005; 19: 655-71.
65. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 1240-4.
66. Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81: 4051-8.
67. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses 2005; 21: 200-6.
68. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 18-26.
69. McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 2005; 90: 2451-5.
70. Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101: 629-32.
71. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012; 15: 14-21.
72. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006; 3: 382-404.
73. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861-8.
74. Nam HJ, Park HJ, Park NC. Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease? Int J Urol 2011; 18: 796-800.
75. Cavallini G, Biagiotti G, Lo Giudice C. Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations. J Androl 2012; 33: 381-8.
76. Coward RM, Verges D, Smith AB, Carson CC. Testosterone deficiency is similarly prevalent among men presenting with either peyronie's disease or erectile dysfunction. J Sex Med 2012; 9: 3-62.
77. Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med 2014; 11: 1636-45.
78. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010; 7: 1627-56.
79. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-43.
80. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014; 11: 1577-92.
81. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91: 2509-13.
82. Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32: 720-8.
83. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58: 710-7.
84. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813-7.
85. Bhasin S, Cunningam GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
86. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844-53.
87. Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009; 37: 52-61.
88. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. Clin Chem 2008; 54: 458-60.
89. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
90. Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, et al. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 2007; 4: 1485-93.
91. Citron JT, Ettinger B, Rubinoff H, Ettinger VM, Minkoff J, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996; 155: 529-33.
92. Handelsman DJ, Liu PY. Klinefelter's syndrome - a microcosm of male reproductive health. J Clin Endocrinol Metab 2006; 91: 1220-2.
93. Hoppé E, Bouvard B, Royer M, Chappard D, Audran M, et al. Is androgen therapy indicated in men with osteoporosis? Joint Bone Spine 2013; 80: 459-65.
94. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72.
95. Kacker R, Conners W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol 2014; 191: 1072-6.
96. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013; 9: 414-24.
97. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-48.
98. Buvat J, Shabsigh R, Guay A, Gooren L, Torres LO, et al. Hormones, metabolism, aging and men's health. Standard practice in sexual medicine. In: Porst II, Buvat J, editors. Malden. Massachusetts and Oxford, UK: Blackwell Publishing; 2006. p. 225-86.
99. Thomas SR, Evans PJ, Holland PA, Biswas M. Invasive breast cancer after initiation of testosterone replacement therapy in a man - a warning to endocrinologists. Endocr Pract 2008; 14: 201-3.
100. Medras M, Filus A, Jozkow P, Winowski J, Sicinska-Werner T. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat 2006; 96: 263-5.
101. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-5.
102. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
103. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34.
104. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20.
105. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014; 65: 115-23.
106. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83.
107. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol 2012; 62: 757-64.
108. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009; 21: 9-23.
109. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-6.
110. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920-2.
111. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70.
112. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009; 103: 62-4.
113. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639-44.
114. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-41.
115. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013; 25: 24-8.
116. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7.
117. Fabbri A, Giannetta E, Lenzi A, Isidori AM. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin Biol Ther 2007; 7: 1093-106.
118. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-91.
119. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3821-9.
120. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011; 8: 639-54.
121. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469-78.
122. rd, Patrick P, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82: 1661-7.
123. McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, et al. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion. J Sex Med 2012; 9: 594-601.
124. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 2001; 55: 531-6.
125. Jockenhövel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996; 45: 61-71.
126. Pastuszak AW, Mittakanti H, Liu JS, Gomez L, Lipshultz LI, et al. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl 2012; 33: 927-37.
127. Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv 2008; 5: 471-81.
128. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164: 371-5.
129. Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20: 299-306.
130. Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007; 8: 2991-3008.
131. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endocrinol Metab 2000; 85: 964-9.
132. Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 2002; 56: 637-41.
133. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2008; 20: 213-7.
134. Mattern C, Hoffmann C, Morley JE, Badiu C. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 2008; 11: 171-8.
135. Natesto (testosterone) nasal gel. Reference ID: 3514261. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205488s000lbl.
136. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, et al. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 2001; 86: 2869-74.
137. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167: 624-9.
138. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004; 89: 1174-80.
139. Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002; 87: 3125-35.
140. Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013; 189: 647-50.
141. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2012; 110: 573-8.
142. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int 2012; 110: 1524-8.
143. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol 2014; 192: 875-9.
144. Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs 2009; 18: 1947-55.
145. Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med 2013; 10: 1628-35.
146. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190: 419-26.
147. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011; 165: 675-85.
148. Coward RM, Simhan J, Carson CC 3rd. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009; 103: 1179-83.
149. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299-311.
150. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf 2004; 3: 599-606.